MedPath

Ciprofibrate

Generic Name
Ciprofibrate
Drug Type
Small Molecule
Chemical Formula
C13H14Cl2O3
CAS Number
52214-84-3
Unique Ingredient Identifier
F8252JGO9S
Indication

用于Ⅱ型和Ⅳ型高脂血症的治疗。

Associated Conditions
Hyperlipidemias
Clinical Trials
Related News

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

First Posted Date
2025-03-05
Last Posted Date
2025-03-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
2382
Registration Number
NCT06858332

Ciprofibrate and Pre-diabetes

Phase 3
Completed
Conditions
Myocardial Insulin Sensitivity
Impaired Glucose Metabolism
Diastolic Dysfunction
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2018-09-10
Last Posted Date
2021-01-08
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
11
Registration Number
NCT03662984
Locations
🇳🇱

Nutrition and Movement Sciences, Maastricht, Limburg, Netherlands

Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia

Phase 4
Conditions
Hypertension
Hypertriglyceridemia
Interventions
Dietary Supplement: DHA-EPA
First Posted Date
2011-11-29
Last Posted Date
2011-11-29
Lead Sponsor
Hospital Universitario Pedro Ernesto
Target Recruit Count
52
Registration Number
NCT01480687
Locations
🇧🇷

Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Rio de Janeiro, Brazil

Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Phase 4
Completed
Conditions
Dyslipidemia
Hypertension
First Posted Date
2006-07-10
Last Posted Date
2008-01-23
Lead Sponsor
Sanofi
Target Recruit Count
60
Registration Number
NCT00350038
Locations
🇭🇺

Sanofi-aventis, Budapest, Hungary

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy